{"id":55912,"date":"2026-01-30T13:49:38","date_gmt":"2026-01-30T05:49:38","guid":{"rendered":"https:\/\/flcube.com\/?p=55912"},"modified":"2026-01-30T13:49:39","modified_gmt":"2026-01-30T05:49:39","slug":"astrazeneca-commits-14-4b-china-investment-in-cell-therapy-push","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=55912","title":{"rendered":"AstraZeneca Commits $14.4B China Investment in Cell Therapy Push"},"content":{"rendered":"\n<p><strong>AstraZeneca<\/strong> (AZ, <a href=\"https:\/\/www.google.com\/finance\/quote\/AZN:NASDAQ\">NASDAQ:\u202fAZN<\/a>) announced a plan to invest <strong>RMB\u202f100\u202fbillion (USD\u202f14.4\u202fbillion)<\/strong> :in China by 2030 to accelerate pharmaceutical production and R&amp;D capabilities. The investment will focus on <strong>cell therapy and radioconjugates<\/strong>, building on UK\u2011China healthcare synergies to deliver innovative therapies for cancer, blood disorders, and autoimmune diseases to patients in China and globally.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-investment-structure-amp-strategic-focus\">Investment Structure &amp; Strategic Focus<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>AstraZeneca Plc (NASDAQ:\u202fAZN)<\/td><\/tr><tr><td><strong>Investment Amount<\/strong><\/td><td>RMB\u202f100\u202fBillion (USD\u202f14.4\u202fBillion)<\/td><\/tr><tr><td><strong>Timeline<\/strong><\/td><td>By 2030<\/td><\/tr><tr><td><strong>Strategic Areas<\/strong><\/td><td>Cell therapy, radioconjugates<\/td><\/tr><tr><td><strong>Value Chain<\/strong><\/td><td>Drug discovery \u2192 clinical development \u2192 manufacturing<\/td><\/tr><tr><td><strong>Therapeutic Focus<\/strong><\/td><td>Cancer, blood disorders, autoimmune diseases<\/td><\/tr><tr><td><strong>China Headcount Target<\/strong><\/td><td>&gt;20,000 employees<\/td><\/tr><tr><td><strong>R&amp;D Hubs<\/strong><\/td><td>Beijing and Shanghai (global strategic R&amp;D centers)<\/td><\/tr><tr><td><strong>Manufacturing Sites<\/strong><\/td><td>Wuxi, Taizhou, Qingdao, Beijing (upgrades + new facilities)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-manufacturing-amp-r-amp-d-expansion\">Manufacturing &amp; R&amp;D Expansion<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Existing Infrastructure:<\/strong> Current operations supply high\u2011quality medicines to China and <strong>70+ global markets<\/strong><\/li>\n\n\n\n<li><strong>Site Upgrades:<\/strong> Investment will modernize existing production facilities in <strong>Wuxi, Taizhou, Qingdao, and Beijing<\/strong><\/li>\n\n\n\n<li><strong>New Facilities:<\/strong> Additional manufacturing locations to be announced, focusing on cell therapy and radioconjugate production<\/li>\n\n\n\n<li><strong>R&amp;D Footprint:<\/strong> Deepens AstraZeneca\u2019s innovation hubs in Beijing and Shanghai, leveraging China\u2019s scientific research strengths and advanced manufacturing capabilities<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact-amp-strategic-rationale\">Market Impact &amp; Strategic Rationale<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>China Cell Therapy Market:<\/strong> Projected to reach <strong>$15\u202fbillion<\/strong> by 2030; AstraZeneca\u2019s investment positions it as a leader in next\u2011generation therapies<\/li>\n\n\n\n<li><strong>Radioconjugates Growth:<\/strong> Global radiopharmaceutical market growing at <strong>15% CAGR<\/strong>; China manufacturing base enables cost\u2011competitive supply for international markets<\/li>\n\n\n\n<li><strong>Policy Alignment:<\/strong> Investment aligns with China\u2019s \u201cHealthy China 2030\u201d and government incentives for multinational R&amp;D partnerships<\/li>\n\n\n\n<li><strong>Competitive Moat:<\/strong> End\u2011to\u2011end integration from discovery to commercialization creates high barriers versus competitors relying on external partnerships<\/li>\n\n\n\n<li><strong>Patient Access:<\/strong> Domestic production accelerates time\u2011to\u2011market for breakthrough therapies and improves affordability through local manufacturing<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding AstraZeneca\u2019s investment timeline, facility expansions, and market projections. Actual results may differ due to regulatory approvals, competitive dynamics, and macroeconomic conditions affecting China\u2019s healthcare sector.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>AstraZeneca (AZ, NASDAQ:\u202fAZN) announced a plan to invest RMB\u202f100\u202fbillion (USD\u202f14.4\u202fbillion) :in China by 2030 to&#8230;<\/p>\n","protected":false},"author":1,"featured_media":55915,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[130,770,871],"class_list":["post-55912","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","tag-astrazeneca","tag-az","tag-nasdaq-azn"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>AstraZeneca Commits $14.4B China Investment in Cell Therapy Push - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"AstraZeneca (AZ, NASDAQ:\u202fAZN) announced a plan to invest RMB\u202f100\u202fbillion (USD\u202f14.4\u202fbillion) :in China by 2030 to accelerate pharmaceutical production and R&amp;D capabilities. The investment will focus on cell therapy and radioconjugates, building on UK\u2011China healthcare synergies to deliver innovative therapies for cancer, blood disorders, and autoimmune diseases to patients in China and globally.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=55912\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AstraZeneca Commits $14.4B China Investment in Cell Therapy Push\" \/>\n<meta property=\"og:description\" content=\"AstraZeneca (AZ, NASDAQ:\u202fAZN) announced a plan to invest RMB\u202f100\u202fbillion (USD\u202f14.4\u202fbillion) :in China by 2030 to accelerate pharmaceutical production and R&amp;D capabilities. The investment will focus on cell therapy and radioconjugates, building on UK\u2011China healthcare synergies to deliver innovative therapies for cancer, blood disorders, and autoimmune diseases to patients in China and globally.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=55912\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-30T05:49:38+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-30T05:49:39+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/3011.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55912#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55912\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"AstraZeneca Commits $14.4B China Investment in Cell Therapy Push\",\"datePublished\":\"2026-01-30T05:49:38+00:00\",\"dateModified\":\"2026-01-30T05:49:39+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55912\"},\"wordCount\":342,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55912#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/3011.webp\",\"keywords\":[\"AstraZeneca\",\"AZ\",\"NASDAQ: AZN\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=55912#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55912\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=55912\",\"name\":\"AstraZeneca Commits $14.4B China Investment in Cell Therapy Push - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55912#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55912#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/3011.webp\",\"datePublished\":\"2026-01-30T05:49:38+00:00\",\"dateModified\":\"2026-01-30T05:49:39+00:00\",\"description\":\"AstraZeneca (AZ, NASDAQ:\u202fAZN) announced a plan to invest RMB\u202f100\u202fbillion (USD\u202f14.4\u202fbillion) :in China by 2030 to accelerate pharmaceutical production and R&D capabilities. The investment will focus on cell therapy and radioconjugates, building on UK\u2011China healthcare synergies to deliver innovative therapies for cancer, blood disorders, and autoimmune diseases to patients in China and globally.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55912#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=55912\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55912#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/3011.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/3011.webp\",\"width\":1080,\"height\":608,\"caption\":\"AstraZeneca Commits $14.4B China Investment in Cell Therapy Push\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55912#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AstraZeneca Commits $14.4B China Investment in Cell Therapy Push\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"AstraZeneca Commits $14.4B China Investment in Cell Therapy Push - Insight, China&#039;s Pharmaceutical Industry","description":"AstraZeneca (AZ, NASDAQ:\u202fAZN) announced a plan to invest RMB\u202f100\u202fbillion (USD\u202f14.4\u202fbillion) :in China by 2030 to accelerate pharmaceutical production and R&D capabilities. The investment will focus on cell therapy and radioconjugates, building on UK\u2011China healthcare synergies to deliver innovative therapies for cancer, blood disorders, and autoimmune diseases to patients in China and globally.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=55912","og_locale":"en_US","og_type":"article","og_title":"AstraZeneca Commits $14.4B China Investment in Cell Therapy Push","og_description":"AstraZeneca (AZ, NASDAQ:\u202fAZN) announced a plan to invest RMB\u202f100\u202fbillion (USD\u202f14.4\u202fbillion) :in China by 2030 to accelerate pharmaceutical production and R&D capabilities. The investment will focus on cell therapy and radioconjugates, building on UK\u2011China healthcare synergies to deliver innovative therapies for cancer, blood disorders, and autoimmune diseases to patients in China and globally.","og_url":"https:\/\/flcube.com\/?p=55912","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-01-30T05:49:38+00:00","article_modified_time":"2026-01-30T05:49:39+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/3011.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=55912#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=55912"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"AstraZeneca Commits $14.4B China Investment in Cell Therapy Push","datePublished":"2026-01-30T05:49:38+00:00","dateModified":"2026-01-30T05:49:39+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=55912"},"wordCount":342,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=55912#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/3011.webp","keywords":["AstraZeneca","AZ","NASDAQ: AZN"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=55912#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=55912","url":"https:\/\/flcube.com\/?p=55912","name":"AstraZeneca Commits $14.4B China Investment in Cell Therapy Push - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=55912#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=55912#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/3011.webp","datePublished":"2026-01-30T05:49:38+00:00","dateModified":"2026-01-30T05:49:39+00:00","description":"AstraZeneca (AZ, NASDAQ:\u202fAZN) announced a plan to invest RMB\u202f100\u202fbillion (USD\u202f14.4\u202fbillion) :in China by 2030 to accelerate pharmaceutical production and R&D capabilities. The investment will focus on cell therapy and radioconjugates, building on UK\u2011China healthcare synergies to deliver innovative therapies for cancer, blood disorders, and autoimmune diseases to patients in China and globally.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=55912#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=55912"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=55912#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/3011.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/3011.webp","width":1080,"height":608,"caption":"AstraZeneca Commits $14.4B China Investment in Cell Therapy Push"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=55912#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"AstraZeneca Commits $14.4B China Investment in Cell Therapy Push"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/3011.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/55912","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=55912"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/55912\/revisions"}],"predecessor-version":[{"id":55916,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/55912\/revisions\/55916"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/55915"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=55912"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=55912"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=55912"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}